Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] ISU PETASYS(007660) – Decision on Cash/In-Kind Dividend / 2025-02-12

Posted on February 12, 2025August 1, 2026 By K-STOCK Editor No Comments on [Disclosure] ISU PETASYS(007660) – Decision on Cash/In-Kind Dividend / 2025-02-12

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

ISU PETASYS resolved to pay a year-end cash dividend of KRW 150 per common share (totaling approximately KRW 9.49 billion) with a record date of March 31, 2025.

📊 [Key Disclosure Details & Financial Figures]

  • Disclosure Type: Decision on Cash/In-Kind Dividend
  • Company Name: ISU PETASYS (Stock Code: 007660)
  • Dividend Type: Year-End Dividend / Cash Dividend
  • Dividend per Share: Common Stock KRW 150 (Preferred Stock N/A)
  • Differential Dividend: N/A
  • Dividend Yield: Common Stock 0.4% (Based on average share price over 1 week prior to board resolution date)
  • Total Dividend Amount: KRW 9.5B (9,486,962,850 KRW)
  • Record Date: March 31, 2025
  • Scheduled Payment Date: To be paid within 1 month from AGM approval (pursuant to Article 464-2 of Commercial Act)
  • Annual General Meeting (AGM): Scheduled for March 31, 2025
  • Board Resolution Date: February 12, 2025 (1 Independent Director attended, Auditor attended)
  • Other Notes: Figures are based on K-IFRS internal accounting estimates and are subject to change based on external audit results and AGM approval.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of AGM Approval and Final Dividend Execution

This disclosure officially establishes the board-approved year-end cash dividend proposal of KRW 150 per share for the 2024 fiscal year. Confirming that the dividend proposal is approved without modification at the Annual General Meeting on March 31, 2025, is important for verifying the actual execution of shareholder returns. Final details can be verified in the ‘Results of Annual General Meeting’ disclosure and under ‘Shareholder Matters (Dividend Policy)’ in the upcoming Annual Report filed on DART.

📢 Disclaimer & Source Notice

Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hanmi Semiconductor (042700) – Decision on Cash/In-Kind Dividend / 2025-02-12
Next Post: [Disclosure] Celltrion (068270) – Approval of Korean MFDS Marketing Authorization for Avtozma Subcutaneous Injection (CT-P47, Actemra Biosimilar) / 2025-02-13

Related Posts

[Disclosure] Hanmi Semiconductor (042700) – New Facility Investment (Voluntary Disclosure) / 2025-06-20 Semiconductors
[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in the US / 2024-12-27 Disclosures
[Disclosure] Samsung Electro-Mechanics (009150) – Advance Notice of Earnings Release / 2024-07-10 Disclosures
[Disclosure] SK Hynix (000660) – Announcement of Investor Relations (IR) Event / 2025-01-09 Disclosures
[Disclosure] Hanmi Semiconductor (042700) – Single Sales and Supply Contract / 2025-05-16 Semiconductors
[Disclosure] Hanwha Aerospace (012450) Corrects Schedule for Q4 2024 IR Meeting to Feb 11 at 9:00 AM Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme